The ROIC Quality of Walgreens Boots Alliance, Inc. Vanguard Group Inc. now owns 69,985,653 shares of the pharmacy operator's stock worth $5,480,577,000 after acquiring an additional 1,926,108 shares during the last quarter. Hedge funds and other institutional investors own 60.09% of the company's stock. Commonwealth Bank of Australia lifted its holdings in Walgreens Boots Alliance by 139.5% in the second quarter. (NASDAQ:WBA) has been trading in a bearish manner, based on the relative positions of the stock's 20 and 200 day moving averages. Capital World Investors increased its stake in shares of Walgreens Boots Alliance by 11.5% in the second quarter. IBM Retirement Fund now owns 22,903 shares of the pharmacy operator's stock valued at $2,004,000 after buying an additional 10,729 shares in the last quarter. Macquarie Group Ltd.'s holdings in Walgreens Boots Alliance were worth $1,934,000 as of its most recent filing with the Securities & Exchange Commission. BlackRock Investment Management LLC now owns 2,821,496 shares of the pharmacy operator's stock worth $234,946,000 after buying an additional 1,092,180 shares in the last quarter. Bristlecone Advisors LLC bought a new position in Walgreens Boots Alliance in the 3rd quarter worth approximately $135,000. Zions Bancorporation lifted its holdings in Walgreens Boots Alliance by 983.3% during the third quarter. Hanson McClain Inc. now owns 1,987 shares of the pharmacy operator's stock worth $156,000 after purchasing an additional 87 shares during the period.
Always volatility measures make charm for active trader; price volatility of stock was 1.81% for a week and 1.62% for a month. The share price has moved forward from its 20 days moving average, trading at a distance of 3.44% and stays 6.02% away from its 50 days moving average.
Any given stock may have anywhere between 1 to 40 brokerage analysts making EPS estimates as they follow the company. It is calculated by multiplying a company's shares outstanding by the current market price of one share. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
In other Walgreens Boots Alliance news, Director William C. Foote sold 2,736 shares of the firm's stock in a transaction that occurred on Thursday, November 2nd. Also, Director John Anthony Lederer acquired 20,000 shares of Walgreens Boots Alliance stock in a transaction on Thursday, October 26th. Following the completion of the transaction, the director now owns 50,000 shares in the company, valued at $3,350,000. The disclosure for this purchase can be found here. The firm owned 16,174 shares of the pharmacy operator's stock after selling 12,890 shares during the period.
A number of equities research analysts recently issued reports on WBA shares. Raymond James Financial restated a "market perform" rating on shares of Walgreens Boots Alliance in a report on Wednesday, September 27th. Vetr upgraded Walgreens Boots Alliance from a "buy" rating to a "strong-buy" rating in a report on Tuesday, December 12th. (NASDAQ:WBA) received a Buy rating from 4 analysts. Finally, SunTrust Banks set a $72.00 price target on Walgreens Boots Alliance and gave the company a "hold" rating in a report on Sunday, October 15th.
According to the Recommendation Trends of the stock polled by Zacks Investment Research for this month, the company has a consensus recommendation of 1.47 out of the scale from 1 to 5 where 1 stands for Strong Buy and 5 means Strong Sell. Investors who observing the volume trend of Walgreens Boots Alliance, Inc. The MF Rank of Walgreens Boots Alliance, Inc. The company has a market cap of $75,340.00, a price-to-earnings ratio of 21.01, a P/E/G ratio of 1.29 and a beta of 1.22. The company has a debt-to-equity ratio of 0.48, a quick ratio of 0.47 and a current ratio of 0.96. The 52-Week High range of the stock is $117.65, while the 52-week low range is $74.67.
Walgreens Boots Alliance (NASDAQ:WBA) last posted its earnings results on Thursday, January 4th. The pharmacy operator reported $1.28 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $1.27 by $0.01. The company had revenue of $30.74 billion for the quarter, compared to the consensus estimate of $30.39 billion. The Gross Margin Score of Walgreens Boots Alliance, Inc. The business's revenue for the quarter was up 7.9% compared to the same quarter a year ago. Over the last five days, shares have managed 5.28% gains and now is down -2.86% since hitting its 200-day moving average of $75.3. BioCryst Pharmaceuticals, Inc. has 2 buy ratings, 2 holds and 0 sells even after the stock tumbled -38.81% from its high of $9.25 to a $571.83 million market value through last close.
Companies that can consistently grow earnings at a high compound rate usually have the greatest potential to create value for shareholders in the long-run. If you are viewing this report on another publication, it was illegally stolen and republished in violation of worldwide copyright & trademark law. If you are viewing this story on another website, it was copied illegally and reposted in violation of United States & global trademark and copyright legislation. The legal version of this story can be viewed at https://www.thelincolnianonline.com/2018/01/13/cubist-systematic-strategies-llc-increases-stake-in-walgreens-boots-alliance-inc-wba.html.
Walgreens Boots Alliance, Inc (Walgreens Boots Alliance) is a holding company.
- Bring on Tennessee! Patriots to host Titans in AFC Divisional matchup
- Oil Prices Spike Amid Extremely Large API Crude Oil Draw (USO)
- Cummins Inc. (CMI) Given Average Recommendation of "Hold" by Analysts
- Florida Monkeys May Infect Humans With Possibly Fatal Herpes Virus
- Stifel Financial Corp Trims Position in Lithia Motors Inc (LAD)
- Donald Trump denies derogatory country remarks
- Discover Financial Services' (DFS) "Market Perform" Rating Reaffirmed at Wells Fargo & Co
- EPS for LPL Financial Holdings Inc. (LPLA) Expected At $0.41
- Tamil Nadu transport unions withdraw strike, to resume work from Friday
- Murder suspect a serial killer